Trial · NCT06458036
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
NCT06458036, Phase 2, Recruiting, Children's Hospital of Philadelphia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE). Trials, record NCT06458036. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06458036
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
- NCT number
- NCT06458036
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 13 participants, estimated
- Lead sponsor
- Children's Hospital of Philadelphia
- Conditions
- Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
- Interventions
- Selpercatinib Monotherapy, 131I Therapy
- First posted
- 2024-06-13
- Last updated
- 2026-07-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of patients with complete overall, pulmonary, structural, and biochemical response. | 18 months | Determine the overall, pulmonary, structural, and biochemical response rate to selpercatinib in patients with RET fusion differentiated thyroid cancer treated with 6 months of selpercatinib prior to 131I therapy |
| Primary | Number of patients who survive without progression of disease after 5 years following protocol treatment. | 5 years | Determine the progression free survival to the combination of selpercatinib followed 6 months later 131I therapy from the initiation of selpercatinib therapy |
| Primary | Proportion of all patients enrolled who show increased radioactive iodine avidity at 6 months following selpercatinib monotherapy. | 6 months | Determine the proportion of patients for whom oncogene-specific, targeted therapy increases tumor RAI-avidity. |
| Primary | The incidence of adverse events and dose limiting toxicity with the combination of selpercatinib and 131I therapy, graded according to CTCAE v5. | 12 months | Determine the safety of the combination of selpercatinib given for 6-months followed by 131I therapy in patients with RET fusion differentiated thyroid cancer |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06458036
GET https://conductscience.org/api/trials/v1/NCT06458036/registered